Skip to main content

What the FDA labels say about taking them together

Lenacapavir and ritonavir

Lenacapavir's FDA label of August 27, 2026 names ritonavir in its drug interactions section; the ritonavir label PlainMeds reads does not name lenacapavir.

Check it at the source: the lenacapavir FDA label on DailyMed (effective August 27, 2026, Gilead Sciences, Inc.); the ritonavir FDA label on DailyMed (effective July 23, 2026, AbbVie Inc.).

What does the lenacapavir label say about ritonavir?

Lenacapavir label, drug interactions

Concomitant Drug Class/Drug Name: Antiretroviral Agents: atazanavir/cobicistat Drug-drug interaction study was conducted. atazanavir/ritonavir; Effect on Concentration ↑ = Increase, ↓ = Decrease.: ↑ lenacapavir (atazanavir/cobicistat, atazanavir/ritonavir); Clinical Comment: Concomitant administration of efavirenz, nevirapine, or tipranavir/ritonavir may result in loss of therapeutic effect and development of resistance.

Source: FDA drug label (Sunlenca), Gilead Sciences, Inc., effective August 27, 2026 (SPL set e5652804-29c4-40d7-aeb2-0142ed2a7b5b), via openFDA; the full label on DailyMed

What does the ritonavir label say about lenacapavir?

Ritonavir's label (effective July 23, 2026) does not name lenacapavir in these sections. A label lists what its studies and reports found; it is not a complete list.

Source: FDA drug label (Norvir), AbbVie Inc., effective July 23, 2026 (SPL set 2849298e-de6e-47bb-8194-56e075b33fc3), via openFDA; the full label on DailyMed

These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.

Both medicines on the record

0Lenacapavir generic labelers
7Ritonavir generic labelers
LenacapavirRitonavir
Labeled forHIVHIV
Boxed warningNoYes
Pharmacy cost (NADAC)n/a$0.607 per tablet 100 mg tablet
Shortage nowNo current entryA presentation being discontinued

Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)

What next?